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Cancer is a major public health concern in terms of morbidity and mortality worldwide. Sev-
eral types of cancer patients suffer from chronic comorbid conditions that are a major clinical
challenge for treatment and cancer management. The main objective of this study was to
investigate the distribution of the burden of chronic comorbid conditions and associated pre-
dictors among cancer patients in Australia over the period of 2007–2017.
Methods
The study employed a prospective longitudinal design using data from the Household,
Income and Labour Dynamics in Australia survey. The number of chronic comorbid condi-
tions was measured for each respondent. The longitudinal effect was captured using a
fixed-effect negative binomial regression model, which predicted the potential factors that
played a significant role in the occurrence of chronic comorbid conditions.
Results
Sixty-one percent of cancer patients experienced at least one chronic disease over
the period, and 21% of patients experienced three or more chronic diseases. Age
(>65 years old) (incidence rate ratio, IRR = 1.15; 95% confidence interval, CI: 1.05, 1.40),
inadequate levels of physical activity (IRR = 1.25; 95% CI: 1.09, 1.59), patients who suf-
fered from extreme health burden (IRR = 2.30; 95% CI: 1.73, 3.05) or moderate health
burden (IRR = 1.90; 95% CI: 1.45, 2.48), and patients living in the poorest households
(IRR = 1.21; 95% CI: 1.11, 1.29) were significant predictors associated with a higher risk
of chronic comorbid conditions.
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Conclusions
A large number of cancer patients experience an extreme burden of chronic comorbid condi-
tions and the different dimensions of these in cancer survivors have the potential to affect
the trajectory of their cancer burden. It is also significant for health care providers, including
physical therapists and oncologists, who must manage the unique problems that challenge
this population and who should advocate for prevention and evidence-based interventions.
Introduction
Cancer is one of the most pressing public health problems worldwide [1]; an estimated 9.6 mil-
lion patients die from cancer each year. In Australia, it is also an alarming issue with the health
system dealing with 483 new cases per 100,000 people in 2019, while on average 136 people die
from cancer each day [2]. Cancer contributes 18% of the total burden of disease in terms of
disability-adjusted life years, followed by 14% from cardiovascular diseases, 13% from muscu-
loskeletal conditions, and 12% from mental and substance use disorders in Australia [3]. Fur-
ther, there are approximately one million survivors in Australia who have been diagnosed with
cancer in the past [4]. The five-year survival from all cancers combined improved from 48% to
69% between 1990 and 2011–2015 [2].
However, the majority of cancer patients suffer from chronic diseases or conditions,
commonly referred to as comorbidity. The risk of having comorbidity increases during
treatment as well as oncology follow-up periods [3,5,6], which adversely influences treat-
ment choices and outcomes. Chronic comorbid conditions of cancer patients contribute to
a major clinical challenge in terms of cancer diagnosis, ill health, the course of treatment,
long-term disability and disease management [7]. In 2014–15, more than 11 million Austra-
lians (50%) reported having at least one chronic disease, wherein approximately 1 in 4 (23%)
Australians had two or more chronic conditions [8]. This rate was more pronounced for
people aged 65 and over (87%) compared with people aged 0–44 (35%), females (52%) com-
pared with males (48%), people in disadvantaged socioeconomic areas (55%) compared with
those in the most advantaged socioeconomic areas (47%), and people living in regional
and remote areas (54%) compared with those in the major cities (48%) [8]. Ultimately, the
severity of comorbidity leads to an increased risk of hospitalisation, reduced health status,
increased mortality, and increased financial burden on the healthcare system [9–11]. It may
also adversely impact an individual’s access to advanced cancer treatments (e.g., chemother-
apy and radiotherapy) and the effectiveness of that treatment [12]. This is a substantial
prognostic factor for the long-term survival of cancer patients. There is a growing body of
research on the significant impact of chronic comorbid conditions among patients with can-
cer. However, there are limited empirical studies on comorbidities available in the Australian
setting [7,13–15].
Comorbidity has a well documented detrimental effect on cancer survival [9] and it
describes the existence of a long-term health condition or disorder in the presence of primary
disease or illness [16]. In the case of cancer, chronic comorbidity refers to the existence of one
or more comorbid conditions in a person simultaneously. While the existence of these comor-
bid health conditions may be extraneous, particularly chronic diseases, there is an association
between them. Further, many chronic diseases share common risk factors. Cancer patients
with comorbid conditions also experience a higher physiological burden of disease [7]. The
presence of specific severe comorbidities or psychiatric disorders is associated with delayed
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cancer diagnosis [11]. Further, patients with chronic diseases with regular medical consulta-
tions and follow-up had their cancer detected at an earlier stage [12].
The chance of improving health status and completing a course of cancer treatment in the
presence of comorbidities is significantly lower among cancer patients [4,13,15,17,18] and is
associated with a higher rate of mortality depending on the severity of disease and associated
comorbidity [11]. For instance, the mortality rate is substantially higher among cancer patients
with comorbidities (47%) compared with cancer patients without comorbidities (34%) [19].
Given the clinical significance of comorbidity and its high prevalence in cancer survivors, it is
essential to have a measure for quantifying likely effects on cancer outcomes [20]. Understand-
ing more about comorbidities among cancer patients can generate possible evidence as well as
provide direction for prevention, management, and treatment of chronic diseases.
A number of studies confirm that comorbid chronic conditions were more pronounced
among cancer patients [4,11,13–15,21,22]. The most prevalent risk factors were age (over 65
years) [23,24], unhealthy behaviors (e.g., alcohol consumption and smoking tobacco) [25,26],
obesity, limited engagement with physical activity [27] and inadequate diet [25] and they are
significantly related to a higher risk of developing cancer along with multiple chronic diseases
[5,7,25]. Further, comorbid conditions of cancer patients are significantly associated with
worse health status during treatment and oncology follow-up periods [28,29] as well as low or
intermediate socioeconomic status [30], and poor nutritional status [31]. The ongoing evidence
shows that modifying or avoiding risk factors can significantly reduce the burden of chronic
comorbid conditions among cancer patients [1]. For example, cancer survivors who engage in
less sedentary behavior enjoy a better quality of life [32], and this can also significantly contrib-
ute to reducing the risk of experiencing chronic comorbid conditions [33].
The primary intention of these studies was to examine the distribution, trend, pattern, and
disparity in comorbidity status among cancer patients when considering a limited range of
variables. The majority of these studies pay little attention to examining the long-term impact
of chronic comorbid conditions for cancer survivors’ over times. Therefore, routine oncology
follow-ups must explore how cancer survivors’ characteristics impact on the number of
chronic comorbid conditions they experience.
This study will examine the longitudinal nature of chronic comorbid conditions of cancer
patients. More specifically, the study proposes to develop a better understanding of the lon-
gitudinal distribution of chronic comorbidity status among cancer patients as well as its
impact over time. This study complements and contributes to this strand of ongoing cancer
research to increase awareness and improve public health practice among sufferers and sur-
vivors, and to measure impact. The findings could contribute to designing appropriate inter-
ventions and/or the provision of quality healthcare services and resources for ongoing
surveillance of people living with, through and beyond cancer, and help determine what
kinds of support survivors need. This study, therefore, aims to investigate the distribution,
potential predictors and associated burden of chronic comorbid conditions among cancer
patients by using a longitudinal data set from the Household, Income and Labour Dynamics
in Australia (HILDA) survey.
Materials and methods
Study design
The study design is a longitudinal exploration using a household-based panel over an extended
period of 2007 to 2017. Individuals who face the burden of life-threatening cancer were inter-
viewed with a focus on the magnitude of the cancer burden associated with their chronic
comorbid conditions. The magnitude of the cancer burden includes their course of treatment
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over an extended oncology follow-up period which can affect their health status burden and
includes chronic comorbid conditions, disability, and adverse events.
Conceptual framework
The distribution of comorbidity varies by patient-level factors (Fig 1). Like cancer itself, it
increases with age. Functional status, a measure of patients’ ability to perform everyday activi-
ties, is related to both the presence and the consequences of chronic comorbid conditions.
Health status burden is associated with increased vulnerability to stressors that result from
decreased health scores as well as physiological strength [34]. Further, health status burden is
strongly associated with increased age and the severity of the disease. In the context of comor-
bidity experiences, patients assess their health status depending on the severity of disease (as
either better or worse) [35]. Despite strong associations between them, comorbidity, functional
status, and health status burden are separate entities, and each has an independent effect on
outcomes [34]. To investigate the longitudinal effects, it is assumed that several predictors
(e.g., individual background characteristics, social factors, and disease-related symptomatic
factors), measured at the symptom-level might predict outcome factors (e.g., appraisal of dis-
ease severity levels, utilisation of advanced treatment, life satisfaction, and uncertainty). More-
over, the combination of predictors was expected to predict patients’ health outcomes (e.g.,
chronic comorbid conditions, long-term health problems or disability, and adverse events).
Data source
Data came from the Household, Income and Labour Dynamics in Australia (HILDA) survey
[36]. The HILDA survey commenced in 2001 and is a nationally representative household-
based panel study that produces data on the lives of Australian residents aged 15 or over. As
per the HILDA protocol, written or verbal consent was collected from all potential participants
before conducting the survey. Data were collected through face-to-face interviews using quanti-
tative survey instruments, followed by re-interviews with the same people in subsequent years.
The details of the methods of data collection, including the sampling technique, have been
explained elsewhere [36]. The present study participants were diagnosed with cancer patients,
Fig 1. Conceptual framework of the study.
https://doi.org/10.1371/journal.pone.0228744.g001
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and data were restricted to four waves (e.g., wave-7, wave-9, wave-13 and wave-17) based on
the availability of data related to cancer. However, wave-3 was excluded from the analysis due
to the limited data related to comorbidity status. Other survey waves were excluded from the
analyses due to the paucity of cancer-related information. A total of 2,066 diagnosed cancer
patients were potential study participants from the four waves: wave-7 in 2007 (n2 = 557),
wave-9 in 2009 (n3 = 416), wave-13 in 2013 (n4 = 517) and wave-17 in 2017 (n5 = 576).
Study variables
Outcome variable. The chronic comorbid conditions were classified into disease groupings
and cover the most common types of long-term health conditions experienced by cancer patients
in the Australian community. A previous review study identified that at least 21 approaches have
been executed to measure comorbidity status [37]. There is no gold-standard method for mea-
suring comorbidity among cancer populations [37]. The selection of the method depends on the
study research question, data availability, and population studied. A number of methods related
to measuring comorbidity status have been used in the context of cancer-related studies includ-
ing exploration of the impact of single conditions (such as diabetes or congestive heart failure)
[38–40], single condition counts [41–43], weighted indices [43–47], and organ-based systems
[48–50]. Although all these approaches aim to evaluate the same underlying construct, they vary
in terms of the study purpose for which the measures were performed. These approaches vary in
the context of study perspective and design. The simplest approach to measuring comorbidity
status is to investigate the distribution of individual comorbid conditions and to treat them inde-
pendently and/or to combine them by summing the total number of conditions [51]. In this
study, a single condition count approach was performed to measure comorbidity status. Cancer
patients reporting chronic condition(s) were considered an outcome variable in the analysis.
Chronic comorbid conditions included being diagnosed with serious chronic illness, including
arthritis or osteoporosis, heart disease, diabetes, hypertension, mental illness, or circulatory con-
ditions. The count of chronic health conditions was measured for each respondent based on the
number of disease exposures and who had been prescribed medication for their illness. If the
respondents had multiple chronic conditions, it was counted as multiple responses.
Explanatory variables. This study considered several demographic, socio-economic and
health and lifestyle-related variables based on the conceptual framework, as putative predictors
of chronic comorbid conditions. Socio-demographic factors, such as sex, age, educational
achievement, employment status, and marital status were considered as potential factors in the
analysis. Lifestyle factors such as alcohol consumption, smoking exposure, and physical activity
were also included. The level of physical activity was categorized into three groups as low, mod-
erate, or high [27,52,53]. Further, life condition-related factors such as satisfaction with
employment, financial situation, and social supports were also selected as potential predictors.
Ethnic status was defined as Aboriginal or non-Aboriginal. The quality of life scores was mea-
sured using the medical outcomes study short-form (SF-36) [54]. The SF-36 is one of the most
common generic measures of health-related quality of life, which is widely used to assess the
burden of disease in the context of different country settings [55]. It uses psychometric proper-
ties to enable profiling of physical functional health and well-being and to quantify disease
burden across eight domains, including physical functioning, role-physical, body pain, general
health, vitality, social functioning, role-emotional, and mental health. Considering these
dimensions, the total score on each SF-36 subscale ranges between 0 and 100, labelling ‘worst
imaginable health’ and ‘best imaginable health state’, respectively. It is signified that the higher
scores represent better health status. A recent review study confirmed that several studies used
a total score of SF-36 items to derive quality of life scores across the eight domains of SF-36
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[56]. The levels of health status burden were proposed based on the magnitude of quality of life
scores as follows: (1) high burden if the short form-36 (SF-36) scores < 50.00, (2) moderate
burden if 50.00�SF-36 scores< 90.00, and (3) no burden if SF-36 scores� 90.00. The level of
health status burden captured the severity of disease for cancer patients. Work disability was
measured based on the severity of disability score ranged from 0 to 10, with 10 indicating ‘able
to do any work’ and 0 indicating ‘not at all’. The severity of disability level was defined as fol-
lows: (i) ‘no disability’ if disability score was equal to zero, (ii) ‘moderate disability’ for disability
scores of 1 to 6, and (iii) ‘severe disability’ for disability scores of 7 to 10. Geographical locations
were defined according to the accessibility to services and the Remoteness Index of Australia
[57], and they were categorized into five groups: major cities, inner regional, outer regional and
remote or very remote. The index of relative socioeconomic disadvantage (IRSD) was used to
measure socioeconomic status (SES). The index was defined into five groups with these thresh-
old values: Q1 (IRSD� 927.0), Q2 (927.0> IRSD� 965.8), Q3 (965.8> IRSD� 1001.8),
Q4 (1001.8> IRSD� 1056.0), or Q5 (IRSD> 1056.0) [58]. This is a geographical area-based
estimate of socioeconomic status using income, education level and occupation where commu-
nities are categorised from economically disadvantaged to wealthy.
Statistical analysis
This study utilised descriptive analyses to compare patients with cancer and chronic medical
conditions across the characteristics. The trend of chronic comorbid conditions among cancer
patients was performed using the Cochran-Armitage trend test [59]. In the analytical explora-
tion, the adjusted fixed-effect negative binomial regression model was used to identify the
potential factors that had a significant role in the exposure to chronic comorbid conditions. In
the regression model, the dependent variable (number of chronic comorbid conditions) was
characterised as a count measure. An unadjusted analysis was performed using only separated
explanatory variables for the following reasons: (1) primary screening of the selection of quali-
fied predictors, which were added in the adjusted model, (2) although the chi-square tests (or
one-way analysis where appropriate) are only used to find the association between outcome
and explanatory variables. However, the majority of the predictor variables were categorical
nature with two or more labels in this study. Therefore, an un-adjusted analysis was performed
to find the association between outcome and the labels of explanatory variables. The predictor
variables were included in the adjusted model only if any label of the predictor was significant
at 5% or less risk level in the unadjusted model, which in turn was used to adjust for the effects
of other potential confounders. However, insignificant predictors were not included in the
adjusted model. The model was tested for sensitivity by the forward selection procedure (e.g.,
including and excluding specific variables) with robust standard errors. For the independent
variables, the category found to be least at risk of having chronic comorbid conditions in the
analysis was considered as the reference for constructing incidence risk ratios (IRR). Statistical
significance was considered at the 5% risk level. All data analyses were undertaken using the
statistical software Stata/SE 13 (StataCorp, College Station, TX, USA).
Ethical considerations
The Household, Income and Labour Dynamics in Australia (HILDA) data are used under
strict licensing. Data can be potentially obtained and shared subject to a peer-reviewed applica-
tion. Ethical approval for the HILDA study was obtained from the Faculty of Business and
Economics Human Ethics Advisory Committee at the University of Melbourne (#1647030).
Approval for the use of HILDA data was provided by the Department of Social Services. Ethical
approval was not required from an institutional review board because the patient information
The burden of chronic diseases among Australian cancer patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0228744 February 12, 2020 6 / 20
was de-identified. Appropriate approval was obtained for this study from the Department of
Social Services to access the de-identified longitudinal dataset.
Results
Background characteristics of the study population
A total of 2,066 cancer patients were potential participants (Tables 1 and 2). Approximately
54% of patients were male, with 58% of patients being married. A higher proportion (46%)
of the patients were senior or old senior-aged (more than 65 years), followed by middle-aged
(37%). Approximately 47% had completed middle or high school level education, with 316
cancer patients (15%) having tertiary education. Sixty three percent of 63% of patients were
unemployed, while 45% of patients had inadequate physical activity, with only 23% of patients
having high-level physical activities per week. Two-third of 75% of patients consumed alcohol
frequently. The majority of participants (89%) reported a moderate or extreme health burden,
whereas 42% of patients experienced moderate or severe disability levels. In addition, 72%
received prescribed medication, and 61% lived in major cities.
Distribution and changes of chronic comorbid conditions with cancer
patients over time
The prevalence of comorbid conditions was reported by cancer patients as follows: arthritis
or osteoporosis (45%), high blood pressure or hypertension (39%), obesity (23%), depression
or anxiety (22%), heart disease (14%), and asthma (13%). These were significantly increased
in the prevalence of depression or anxiety (p<0.01), mental illness (p = 0.052) and obesity
(p = 0.003) over the period (Fig 2). However, a downward trend in the prevalence of comorbid
conditions was observed for arthritis/osteoporosis (p = 0.012) over time.
Overall, approximately 42% of patients suffered from one to two chronic comorbid condi-
tions, while 21% of patients experienced at least three or more comorbid conditions (Table 1).
The prevalence of comorbid conditions was prominently distributed by age. The majority of
comorbidities were highly pronounced in patients due to a lack of physical activity. For exam-
ple, 56% of patients were more likely to report three or more comorbid conditions. This preva-
lence was disproportionately low (14%) in those who engaged in a high level of physical activity.
Further, patients who suffered from at least one comorbid condition were significantly aligned
with the magnitude of high or moderate health status burden (e.g., 62% for severe burden and
36% for moderate burden). Similarly, an upward trend of the upper extremity of disability levels
was observed with an increased number of comorbid exposures among the poorest cancer sur-
vivors during the period (Fig 3). Regarding socioeconomic position, the magnitude of comorbid
conditions was more pronounced in the most disadvantaged socio-economic group. For exam-
ple, 28% of patients who lived in the poorest households were significantly exposed to three or
more comorbid conditions compared with the richest households (13%). Also, the severity of
disability score was also highest among patients in the poorest households along with an
increasing number of comorbid conditions (Fig 3).
Factors influencing chronic comorbid exposure of cancer patients
Table 3 exhibits the results of the fixed effect negative binomial regression analyses. In the
adjusted model, older patients, the magnitude of health status burden associated with cancer,
utilisation of healthcare, and patients living in the poorest households were significant predic-
tors associated with a higher risk of comorbid conditions. An aged patient (>65 years old) has
1.15 times higher risk of having comorbid conditions (incidence rate ratio, IRR = 1.15; 95%
The burden of chronic diseases among Australian cancer patients
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Table 1. Summary statistics by the number of chronic condition among cancer patients for wave 7 and wave 9.
Variables Number of observations, n (%) Wave-7 Wave-9
Number of chronic comorbid conditions, n
(%)
Number of chronic comorbid conditions, n
(%)
0 1–2 3 or more 0 1–2 3 or more
Sex
Male 1,123 (54.36) 234 (54.80) 77 (59.23) na 45 (51.14) 110 (48.46) 55 (54.46)
Female 943 (45.64) 193 (45.20) 53 (40.77) na 43 (48.86) 117 (51.54) 46 (45.54)
Age
<25 years 53 (2.57) 10 (2.34) 3 (2.31) na 1 (1.14) 4 (1.76) 1 (0.99)
25–45 years 283 (13.70) 77 (18.03) 17 (13.08) na 23 (26.14) 32 (14.10) 8 (7.92)
46–65 years 771 (37.32) 146 (34.19) 69 (53.08) na 39 (44.32) 86 (37.89) 30 (29.7)
>65 years 959 (46.42) 194 (45.43) 41 (31.54) na 25 (28.41) 105 (46.26) 62 (61.39)
Educational attainment
Year 11 or below 774 (37.46) 169 (39.58) 48 (36.92) na 26 (29.55) 97 (42.73) 46 (45.54)
Year 12 168 (8.13) 37 (8.67) 14 (10.77) na 10 (11.36) 15 (6.61) 9 (8.91)
Trade/certificate/diploma 808 (39.11) 149 (34.89) 54 (41.54) na 35 (39.77) 81 (35.68) 40 (39.6)
Tertiary 316 (15.30) 72 (16.86) 14 (10.77) na 17 (19.32) 34 (14.98) 6 (5.94)
Unemployed 1,306 (63.21) 250 (58.55) 66 (50.77) na 40 (45.45) 150 (66.08) 86 (85.15)
Marital status
Single 258 (12.49) 52 (12.18) 20 (15.38) na 16 (18.18) 27 (11.89) 7 (6.93)
Married 1,196 (57.89) 256 (59.95) 80 (61.54) na 46 (52.27) 130 (57.27) 52 (51.49)
Others 612 (29.62) 119 (27.87) 30 (23.08) na 26 (29.55) 70 (30.84) 42 (41.58)
Alcohol consumption (= yes) 1,500 (72.60) 341 (79.86) 102 (78.46) na 64 (72.73) 158 (69.60) 66 (65.35)
Smoking exposure (= yes) 276 (13.36) 64 (14.99) 22 (16.92) na 11 (12.50) 32 (14.10) 13 (12.87)
Physical activity status
Low 876 (42.40) 153 (55.11) 88 (55.11) 36 (55.11) 98 (55.11) 52 (55.11)
Moderate 701 (33.93) 134 (29.55) 30 (29.55) 28 (29.55) 74 (29.55) 33 (29.55)
High 489 (23.67) 140 (15.34) 12 (15.34) 24 (15.34) 55 (15.34) 16 (15.34)
Health status burden
No burden 208 (10.07) 57 (13.35) 13 (10.00) na 24 (27.27) 19 (8.37) 1 (0.99)
Moderate burden 1,205 (58.33) 268 (62.76) 82 (63.08) na 48 (54.55) 135 (59.47) 41 (40.59)
Severe burden 653 (31.61) 102 (23.89) 35 (26.92) na 16 (18.18) 73 (32.16) 59 (58.42)
Disability status
No disability 1,172 (56.73) 258 (60.42) 76 (58.46) na 76 (86.36) 124 (54.63) 32 (31.68)
Moderate disability 509 (24.64) 92 (21.55) 26 (20.00) na 7 (7.95) 63 (27.75) 39 (38.61)
Severe disability 385 (18.64) 77 (18.03) 28 (21.54) na 5 (5.68) 40 (17.62) 30 (29.70)
Healthcare utilisation (= yes) 1,093 (72.43) 219 (65.45) 63 (46.95) na 22 (25.00) 181 (79.74) 98 (97.03)
Life satisfaction with-
Employment, mean (sd) 3.39 (3.96) 3.51 (4.03) 3.86 (3.94) na 5.3 (3.98) 3.55 (3.98) 2.36 (3.88)
Financial situation, mean (sd) 6.73 (2.37) 7.05 (2.27) 6.65 (2.43) na 6.98 (2.14) 6.63 (2.45) 6.04 (2.59)
Social supports, mean (sd) 7.83 (1.82) 8.09 (1.54) 7.97 (1.54) na 7.91 (1.73) 7.64 (2.03) 7.78 (1.98)
Remoteness
Major Cities 1,264 (61.18) 270 (63.23) 75 (57.69) na 48 (54.55) 128 (56.39) 63 (62.38)
Inner Regional 519 (25.12) 98 (22.95) 34 (26.15) na 24 (27.27) 59 (25.99) 24 (23.76)
Outer Regional 247 (11.96) 50 (11.71) 21 (16.15) na 13 (14.77) 38 (16.74) 12 (11.88)
Remote or very remote 36 (1.74) 9 (2.11) na na 3 (3.41) 2 (0.88) 2 (1.98)
Socioeconomic status
Q1 (lowest 20%) (ref) 407 (19.70) 81 (18.97) 23 (17.69) na 11 (12.50) 46 (20.26) 27 (26.73)
(Continued)
The burden of chronic diseases among Australian cancer patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0228744 February 12, 2020 8 / 20
confidence interval, CI: 1.08, 1.45) compared with a young patient (<25 years). Patients who
performed lower levels of physical activity were 1.25 times more likely to have a chronic
comorbid condition (IRR = 1.25; 95% CI: 1.09, 1.59) compared with patients who engaged in
high-level physical activity. Further, patients who faced an extreme health burden were 2.30
times significantly higher risk of having comorbid conditions than those with no health bur-
den. The risks of having a comorbid condition were more pronounced among patients who
suffered from extreme health burden (IRR = 2.30 times) or moderate burden level (IRR = 1.90
times) compared with patients who reported excellent health status. Similarly, a higher risk of
having a comorbid exposure was significantly observed in cancer patients who lived in the
poorest households (IRR = 1.21; 95% CI: 1.11, 1.29) compared with their richest counterparts.
Discussion
The study results show that approximately 63% of cancer patients suffered from at least one
chronic disease. The most prevalent comorbid conditions were arthritis or osteoporosis, high
blood pressure or hypertension, obesity, depression or anxiety, heart disease, and asthma.
However, these were significantly increased in the presence of diabetes, depression or anxiety,
mental illness, heart disease and obesity over time. In the adjusted model, older patients, inad-
equate level of physical activities, the magnitude of health burden associated with cancer, utili-
sation of healthcare, and patients living in the poorest households were significant predictors
associated with a higher risk of comorbid conditions.
Further, patients who faced an extreme health burden had a three times higher risk of hav-
ing comorbid conditions than who reported excellent health status. Some studies have con-
firmed that the poor health status of cancer patients resulted in a greater burden of functional
disability (e.g., specific task difficulties) [60,61] along with a higher burden of chronic diseases
[15,30,62]. However, the prevalence of long-term health problems, including chronic illness,
short or long-term disability, was also more concentrated in combination with a cancer diag-
nosis [63–68]. Advanced cancer treatments can damage healthy cells or organs [69], for exam-
ple, radiation and chemotherapy may impose short and long-term chronic health problems
and impact on the spinal cord, nerves, and brain, which then may significantly contribute to
long-term adverse health outcomes like death, physical and mental disabilities.
The results indicate that aged cancer patients (older than 65 years) were at a 1.15 times
higher risk of having chronic comorbid conditions compared with younger patients. This find-
ing is consistent with previous studies, which revealed that elderly cancer patients reported sig-
nificantly more exposure to chronic comorbid conditions [23,70,71], required more assistance
with daily living activities [72], and had deficits in performing work-related activities in terms
Table 1. (Continued)
Variables Number of observations, n (%) Wave-7 Wave-9
Number of chronic comorbid conditions, n
(%)
Number of chronic comorbid conditions, n
(%)
0 1–2 3 or more 0 1–2 3 or more
Q2 470 (22.75) 87 (20.37) 27 (20.77) na 16 (18.18) 60 (26.43) 29 (28.71)
Q3 369 (17.86) 79 (18.50) 33 (25.38) na 25 (28.41) 39 (17.18) 14 (13.86)
Q4 428 (20.72) 98 (22.95) 28 (21.54) na 20 (22.73) 39 (17.18) 21 (20.79)
Q5 (highest 20%) 392 (18.97) 82 (19.20) 19 (14.62) na 16 (18.18) 43 (18.94) 10 (9.90)
Overall 2,066 (100) 427 (76.66) 130 (23.34) na 88 (21.15) 227 (54.57) 101 (24.28)
Na = not available
https://doi.org/10.1371/journal.pone.0228744.t001
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Table 2. Summary statistics by the number of chronic condition among cancer patients for wave 13 and wave 17.
Variables Wave-13 Wave-17 Overall
Number of chronic comorbid conditions,
n (%)
Number of chronic comorbid conditions,
n (%)
Number of chronic comorbid conditions,
n(%
0 1–2 3 or more 0 1–2 3 or more 0 1–2 3 or more
Sex
Male 70 (58.82) 122 (50.41) 87 (55.77) 73 (57.94) 160 (58.39) 90 (51.14) 422 (55.53) 469 (53.72) 232 (53.58)
Female 49 (41.18) 120 (49.59) 69 (44.23) 53 (42.06) 114 (41.61) 86 (48.86) 338 (44.47) 404 (46.28) 201 (46.42)
Age
<25 years 6 (5.04) 9 (3.72) 2 (1.28) 6 (4.76) 5 (1.82) 6 (3.41) 23 (3.03) 21 (2.41) 9 (2.08)
25–45 years 25 (21.01) 30 (12.4) 9 (5.77) 26 (20.63) 28 (10.22) 8 (4.55) 151 (19.87) 107 (12.26) 25 (5.77)
46–65 years 51 (42.86) 93 (38.43) 47 (30.13) 56 (44.44) 98 (35.77) 56 (31.82) 292 (38.42) 346 (39.63) 133 (30.72)
>65 years 37 (31.09) 110 (45.45) 98 (62.82) 38 (30.16) 143 (52.19) 106 (60.23) 294 (38.68) 399 (45.7) 266 (61.43)
Educational attainment
Year 11 or below 31 (26.05) 88 (36.36) 70 (44.87) 30 (23.81) 91 (33.21) 78 (44.32) 256 (33.68) 324 (37.11) 194 (44.8)
Year 12 9 (7.56) 20 (8.26) 8 (5.13) 12 (9.52) 21 (7.66) 13 (7.39) 68 (8.95) 70 (8.02) 30 (6.93)
Trade/certificate/diploma 51 (42.86) 107 (44.21) 59 (37.82) 47 (37.3) 117 (42.7) 68 (38.64) 282 (37.11) 359 (41.12) 167 (38.57)
Tertiary 28 (23.53) 27 (11.16) 19 (12.18) 37 (29.37) 45 (16.42) 17 (9.66) 154 (20.26) 120 (13.75) 42 (9.7)
Unemployed 58 (48.74) 159 (65.70) 128 (82.05) 54 (42.86) 177 (64.60) 138 (78.41) 402 (52.89) 552 (63.23) 352 (81.29)
Marital status
Single 21 (17.65) 30 (12.4) 12 (7.69) 24 (19.05) 30 (10.95) 19 (10.8) 113 (14.87) 107 (12.26) 38 (8.78)
Married 72 (60.5) 141 (58.26) 90 (57.69) 69 (54.76) 164 (59.85) 96 (54.55) 443 (58.29) 515 (58.99) 238 (54.97)
Others 26 (21.85) 71 (29.34) 54 (34.62) 33 (26.19) 80 (29.2) 61 (34.66) 204 (26.84) 251 (28.75) 157 (36.26)
Alcohol consumption (= yes) 91 (76.47) 178 (73.55) 100 (64.10) 84 (66.67) 205 (74.82) 111 (63.07) 580 (76.32) 643 (73.65) 277 (63.97)
Smoking exposure (= yes) 11 (9.24) 32 (13.22) 23 (14.74) 14 (11.11) 32 (11.68) 22 (12.50) 100 (13.16) 118 (13.52) 58 (13.39)
Physical activity status
Low 35 (29.41) 95 (39.26) 94 (60.26) 50 (39.68) 125 (45.62) 97 (55.11) 274 (36.05) 406 (46.51) 243 (56.12)
Moderate 44 (36.97) 81 (33.47) 44 (28.21) 36 (28.57) 89 (32.48) 52 (29.55) 242 (31.84) 274 (31.39) 129 (29.79)
High 40 (33.61) 66 (27.27) 18 (11.54) 40 (31.75) 60 (21.9) 27 (15.34) 244 (32.11) 193 (22.11) 61 (14.09)
Health status burden
No burden 30 (25.21) 15 (6.2) 0 (0) 22 (17.46) 22 (8.03) 5 (2.84) 132 (17.37) 69 (7.9) 6 (1.39)
Moderate burden 64 (53.78) 172 (71.07) 75 (48.08) 76 (60.32) 175 (63.87) 69 (39.2) 422 (55.53) 513 (58.76) 156 (36.03)
Severe burden 25 (21.01) 55 (22.73) 81 (51.92) 28 (22.22) 77 (28.1) 102 (57.95) 206 (27.11) 291 (33.33) 271 (62.59)
Disability status
No disability 96 (80.67) 146 (60.33) 41 (26.28) 104 (82.54) 153 (55.84) 66 (37.50) 534 (70.26) 499 (57.16) 139 (32.10)
Moderate disability 9 (7.56) 59 (24.38) 56 (35.9) 10 (7.94) 84 (30.66) 64 (36.36) 118 (15.53) 232 (26.58) 159 (36.72)
Severe disability 14 (11.76) 37 (15.29) 59 (37.82) 12 (9.52) 37 (13.5) 46 (26.14) 108 (14.21) 142 (16.27) 135 (31.18)
Healthcare utilisation (= yes) 39 (32.77) 175 (72.31) 152 (97.44) 47 (37.30) 209 (76.28) 170 (96.59) 108 (9.88) 565 (51.69) 420 (38.43)
Life satisfaction with-
Employment, mean (sd) 4.82 (3.89) 3.47 (3.9) 1.96 (3.43) 4.48 (3.97) 3.39 (3.97) 1.64 (3.12) 4.08 (4.04) 3.52 (3.95) 1.92 (3.43)
Financial situation, mean (sd) 7.39 (1.98) 6.5 (2.53) 5.99 (2.57) 7.33 (2.01) 6.76 (2.31) 6.32 (2.65) 7.14 (2.17) 6.64 (2.43) 6.13 (2.6)
Social supports, mean (sd) 7.94 (1.68) 7.67 (2.17) 7.74 (1.95) 7.82 (1.74) 7.92 (1.71) 7.44 (2.1) 8 (1.62) 7.78 (1.91) 7.63 (2.02)
Remoteness
Major Cities 79 (66.39) 151 (62.4) 105 (67.31) 91 (72.22) 151 (55.11) 103 (58.52) 488 (64.21) 505 (57.85) 271 (62.59)
Inner Regional 27 (22.69) 55 (22.73) 35 (22.44) 26 (20.63) 87 (31.75) 50 (28.41) 175 (23.03) 235 (26.92) 109 (25.17)
Outer Regional 11 (9.24) 32 (13.22) 16 (10.26) 6 (4.76) 28 (10.22) 20 (11.36) 80 (10.53) 119 (13.63) 48 (11.09)
Remote or very remote 2 (1.68) 4 (1.65) 0 (0) 3 (2.38) 8 (2.92) 3 (1.7) 17 (2.24) 14 (1.6) 5 (1.15)
Socioeconomic status
Q1 (lowest 20%) (ref) 17 (14.29) 50 (20.66) 48 (30.77) 18 (14.29) 41 (14.96) 45 (25.57) 127 (16.71) 160 (18.33) 120 (27.71)
(Continued)
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of their physical ability [60,73]. Several reasons might influence this reduction in their physical
strength. For example, a course of advanced cancer treatment is associated with considerable
physical and psychological side effects in elderly cancer patients (e.g., weight change, muscle
loss, fatigue, and physical weakness) [74], and exposure to multiple comorbidities [64,65,75]
will presumably contribute to worse health status. Although, cancer patients in older age
groups are less likely to be offered cancer treatments (e.g., chemotherapy, radiotherapy and
axillary lymph node dissection) that may then contribute to a greater burden of health [74].
This result indicates that rehabilitation-related interventions (e.g., physical therapies) are
essential to prevent or alleviate chronic comorbid conditions and an emerging cancer research
area, particularly focused on the elderly [76].
The present study found that cancer patients who performed lower levels of physical activi-
ties were strongly associated with an extreme level of chronic comorbidities compared with
patients engaged in high-level physical activity. This finding is in line with other studies
[52,77,78], whereby it was found that limited physical activity levels were significantly associ-
ated with a higher risk of having chronic comorbid conditions in cancer patients. The magni-
tude of limited physical activity level may decrease the risk for several cancers by some
mechanisms, including decreasing sex hormones, metabolic hormones and inflammation, and
improving immune function [77]. In terms of cancer risk, high levels of physical activities
(compared with low levels) played a significant role in the prevention of several cancers (e.g.,
42% for gastrointestinal cancer, 23% for renal cancer, and 20% for myeloid leukemia) [79].
Table 2. (Continued)
Variables Wave-13 Wave-17 Overall
Number of chronic comorbid conditions,
n (%)
Number of chronic comorbid conditions,
n (%)
Number of chronic comorbid conditions,
n(%
0 1–2 3 or more 0 1–2 3 or more 0 1–2 3 or more
Q2 22 (18.49) 59 (24.38) 38 (24.36) 22 (17.46) 62 (22.63) 48 (27.27) 147 (19.34) 208 (23.83) 115 (26.56)
Q3 21 (17.65) 29 (11.98) 27 (17.31) 21 (16.67) 51 (18.61) 30 (17.05) 146 (19.21) 152 (17.41) 71 (16.40)
Q4 32 (26.89) 51 (21.07) 23 (14.74) 27 (21.43) 64 (23.36) 25 (14.20) 177 (23.29) 182 (20.85) 69 (15.94)
Q5 (highest 20%) 27 (22.69) 53 (21.9) 20 (12.82) 38 (30.16) 56 (20.44) 28 (15.91) 163 (21.45) 171 (19.59) 58 (13.39)
Overall 119 (23.02) 242 (46.81) 156 (30.17) 126 (21.88) 274 (47.57) 176 (30.56) 760 (36.79) 873 (42.26) 433 (20.96)
Na = not available
https://doi.org/10.1371/journal.pone.0228744.t002
Fig 2. The trend of disease pattern among patients with cancer.
https://doi.org/10.1371/journal.pone.0228744.g002
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This includes averting genetic damage, improving the immune system, reducing chronic infec-
tions, and controlling cancer cells [79]. In addition, some past studies confirmed that physical
activity plays an effective role in controlling the side effects of cancer treatment and disease
progression, reducing psychological conditions [77,80] and reducing the risk of developing
future cancers [81]. Several hypotheses and mechanisms have been suggested regarding the
anti-cancer effects of physical activities. The American Cancer Society guidelines for cancer
survivors [82] recommend daily physical activities, including a continuation of normal daily
life activities immediately after diagnosis, which help to significantly reduce physical stamina
and muscle strength erosion as well as anxiety levels, thereby resulting in the prevention of
long-term adverse health outcomes (e.g., extreme comorbidity burden and disability) [83]. In
this context, future research could examine the influence that physical activity has on the effec-
tiveness of chronic comorbid conditions among cancer patients.
The risks of having extreme chronic comorbidity conditions amongst cancer patients who
lived in the poorest households were more pronounced compared with their richer counter-
parts. Recent studies confirm this result with the disadvantaged socioeconomic status of cancer
survivors being negatively associated with long-term adverse health outcomes (e.g., multiple
chronic illnesses, physical disability) [83–93]. Some studies also provided evidence that the mag-
nitude of the cancer burden is adversely associated with socioeconomic status [16, 32–35].
Further, adverse cancer outcomes (e.g., worse health status and long-term chronic illness) were
disproportionately found in poorer people as opposed to those of higher socioeconomic status
[13, 16, 32, 34]. Some reasons that have contributed to the high rates of long term health impacts
among the poorest groups include higher tobacco consumption [16,28], economic burden
[36,37], increased mental illness [94], lack of health education and awareness [95], and less
access to competent and effective health care services [95]. Low productivity, loss/reduction of
household income, and increased healthcare expenditure are more pronounced amongst the
poorest cancer patients. Growing socioeconomic disparities of cancer outcomes need the
Fig 3. Unequal distribution of the presence of chronic comorbidities with the severity of disability among cancer patients across socioeconomic
status.
https://doi.org/10.1371/journal.pone.0228744.g003
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Table 3. Factors influencing chronic comorbid conditions of cancer patients using a fixed-effect negative binomial regression model.
Variables Unadjusted model1 Adjusted model2
IRR (SE) 95% CI IRR (SE) 95% CI
Female (ref = male) 1.04 (0.05) (0.94, 1.14) - -
Age group
< 25 years (= ref) 1.00 - 1.00 -
25–45 years 0.72 (0.13) (0.51, 1.03) 0.85 (0.14) (0.61, 1.18)
46–65 years 1.15 (0.19) (0.83, 1.58) 1.07 (0.16) (0.79, 1.45)
>65 years 1.49��� (0.24) (1.09, 2.04) 1.15�� (0.17) (1.08, 1.45)
Educational attainment
Year 11 or below 1.48��� (0.12) (1.26, 1.74) 1.16�� (0.09) (1.01, 1.35)
Year 12 1.11 (0.13) (0.88, 1.40) 1.13 (0.12) (0.91, 1.40)
Trade/certificate/diploma 1.38��� (0.12) (1.17, 1.63) 1.21��� (0.09) (1.05, 1.40)
Tertiary (= ref) 1.00 - 1.00 -
Unemployed (ref = employed) 1.80��� (0.10) (1.62, 2.00) 1.08 (0.07) (0.95, 1.23)
Marital status
Single (= ref) 1.00 - 1.00 -
Married 1.21�� (0.10) (1.02, 1.42) 1.02 (0.08) (0.87, 1.20)
Others 1.41��� (0.12) (1.19, 1.68) 1.06 (0.09) (0.90, 1.25)
Physical activity status
Low 1.60��� (0.12) (1.39, 1.85) 1.25�� (0.07) (1.09, 1.59)
Moderate 1.30��� (0.10) (1.12, 1.52) 1.06 (0.07) (0.92, 1.21)
High (= ref) 1.00 - 1.00 -
Alcohol consumption (ref = yes) 1.26��� (0.06) (1.14, 1.39) 0.91 (0.05) (0.82, 1.00)
Smoking exposure (ref = no) 1.02 (0.07) (0.88, 1.18) - -
Healthcare utilisation (ref = no) 0.27 (0.02) (0.24, 0.31) 0.38��� (0.03) (0.33, 0.45)
Health status burden
No burden (= ref) 1.00 - 1.00 -
Moderate burden 2.44��� (0.27) (1.96, 3.03) 1.90��� (0.26) (1.45, 2.48)
Severe burden 4.18��� (0.47) (3.36, 5.21) 2.30��� (0.33) (1.73, 3.05)
Disability status
No disability (= ref) 1.00 - 1.00 -
Moderate disability 1.82��� (0.10) (1.64, 2.02) 1.22��� (0.07) (1.10, 1.36)
Severe disability 1.99��� (0.12) (1.76, 2.24) 1.25��� (0.08) (1.11, 1.41)
Life satisfaction with-
Employment 0.94��� (0.01) (0.92, 0.95) 0.98��� (0.01) (0.97, 0.99)
Financial situation 0.97�� (0.01) (0.95, 0.99) 0.96��� (0.01) (0.94, 0.98)
Social supports 0.96��� (0.01) (0.93, 0.98) 1.03�� (0.01) (1.01, 1.05)
Remoteness
Major cities (= ref) 1.00 - - -
Inner regional 1.02 (0.06) (0.91, 1.14) - -
Outer regional 1.04 (0.08) (0.90, 1.21) - -
Remote or very remote 0.77 (0.14) (0.54, 1.11) - -
Socioeconomic status
Q1 (lowest 20%) 1.51��� (0.12) (1.29, 1.77) 1.21��� (0.08) (1.11, 1.29)
Q2 1.35��� (0.11) (1.15, 1.57) 1.09 (0.08) (0.95, 1.26)
Q3 1.19�� (0.10) (1.01, 1.41) 1.15 (0.09) (0.99, 1.34)
Q4 1.08 (0.09) (0.92, 1.27) 0.99 (0.08) (0.85, 1.15)
(Continued)
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attention of governments, health systems, and decision-makers. For example, Cancer Council
Australia has an optimal care pathway project, which has already addressed several cancer sites
in disadvantaged areas. Such initiatives might help to reduce socio-economic disparities, which
are related to poverty, gender, education, and health, and they should promote universal access
to health care which can further enhance both socio-economic and human development.
This study has some limitations. Study participants were accessed from the HILDA survey,
which covers health, economic, employment, income and health characteristics of household
members aged 15 years and older. Children who suffered from cancer were excluded from this
study. The study findings established a relationship between cancer diagnosis and chronic
comorbidity conditions among cancer survivors, which might vary in terms of cancer stages
and types of cancer. The authors were not able to estimate the cancer type analysis due to the
paucity of relevant data. Further, the study findings were based on self-reported responses that
might have been impacted by respondents’ prejudice (e.g., silence and over-response), and by
problems in understanding and interpreting the survey questions.
Despite these limitations, this study has some strengths including the use of a prospective
longitudinal design of long term follow-ups and the application of well-validated and reliable
longitudinal wave measures of the impacts of a cancer diagnosis on the burden of chronic
comorbid conditions of individuals over the 2007–2017 period. The study population captured
different dimensions including ethnically, geographically, and socio-economically diverse
groups. Furthermore, this study included several potential confounding factors such as health
status burden, the severity of the disability level as well as life satisfaction (e.g., employment,
financial situation and, social supports) that were not present in previous studies. For this study,
data were gathered from four-wave of the HILDA survey for cancer survivors. The length of the
survey period may have introduced uncontrolled bias, as changes in health status are not instan-
taneous and might emerge only after time, which was not captured in this study. Due to the
paucity of funding, the authors were unable to consider cancer patients who registered for can-
cer surveillance as well as received health care from other health facilities (e.g., private clinics,
community clinics and, secondary or tertiary hospitals). Future study is required using a similar
study design, perspective, and analytical methods in terms of cancer-specific exploration.
Conclusions
This study has shown an extreme burden of chronic comorbid conditions among cancer
patients in Australia. Older patients, inadequate level of physical activities, the magnitude of
health burden, and patients living in the poorest households were significant predictors associ-
ated with a higher risk of having chronic comorbidity conditions. The findings have further
Table 3. (Continued)
Variables Unadjusted model1 Adjusted model2
IRR (SE) 95% CI IRR (SE) 95% CI





IRR = incidence rate ratio, SE = standard error, CI = confidence interval,
1Single explanatory variable was included in un-adjusted model,
2Explanatory variables were included in the adjusted model only if any label of the variable was significant at 5% or less risk level in the unadjusted model
https://doi.org/10.1371/journal.pone.0228744.t003
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implications for improving public health policy and reducing population-level unhealthy life-
styles, which should be recommended. The study results could be used to better outline the
management of a sequelae course of treatment for those who should undergo more intensive
physical rehabilitation aimed at reducing the risk of adverse health outcomes. Given the clini-
cal significance of comorbidity in cancer survivors, this study may play a significant role in
providing comprehensive evidence for health care providers, including physical therapists and
oncologists, who should be aware of the unique problems that challenge this population and
who should advocate for prevention and evidence-based interventions. Finally, a greater
awareness of the importance of managing a patients overall health status within the context of
comorbidity is warranted together with emphasised research on comorbidity to generate an
appropriate scientific basis on which to build evidence-based care guidelines for these chronic
comorbid conditions patients.
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